Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer

Figures & data

Table I. Permanent histological diagnosis of 303 patients.

	Number of the patients (N = 303)
Papillary thyroid cancer	269 (88.8)
Follicular thyroid cancer	8 (3.0)
Medullary thyroid cancer	7 (2.3)
Anaplastic/undifferentiated thyroid cancer	4 (1.3)
Nodular hyperplasia	11 (3.6)
Follicular adenoma	2 (0.7)
Subacute thyroiditis	2 (0.7)

Percentages are given in parentheses.

Table II. Baseline clinicodemographic variables of 269 patients with papillary thyroid cancer (PTC) stratified by the presence of Hashimoto's thyroiditis (HT).

	PTC with HT (n = 58)	PTC alone (n = 211)	p-value
Age (years)	42.8 ± 12.7	48.32 ± 14.4	0.008
Gender (male:female)	1 : 18.33	1 : 4.15	0.009
Extent of surgery
Total thyroidectomy	47 (81)	178 (84.4)	0.544
Without ND^*	29 (50)	111 (52.6)	0.725
With CND^†	13 (22.4)	23 (10.9)	0.023
With C-ND^‡	5 (8.6)	44 (20.9)	0.033
Thyroid lobectomy with isthmusectomy	11 (19)	33 (15.6)	0.544
Duration of hospital stay (days)	5.1 ± 2.9	7.1 ± 6.4	0.001
RLN^§ paralysis
Temporary	4 (6.9)	9 (4.3)	0.408
Permanent	4 (6.9)	16 (7.6)	0.860
Permanent hypocalcemia	5 (8.62)	16 (7.6)	0.723

Percentages are given in parentheses.

*Neck dissection, ^†Central neck dissection, ^‡Comprehensive neck dissection, ^§Recurrent laryngeal nerve.

Table III. Univariate clinicopathological parameters of 269 patients with papillary thyroid cancer (PTC) stratified by the presence of Hashimoto's Thyroiditis (HT).

	PTC with HT (n = 58)	PTC alone (n = 211)	p-value
Sensitivity of FNA^*	91.4%	87.7%	0.251
Subtype of PTC
Conventional	55 (94.8)	203 (96.2)	0.638
Follicular variant	2 (3.5)	7 (3.3)	1.000
Tall cell variant	1 (1.7)	1 (0.5)	0.385
Tumour size (cm)	1.6 ± 1.0	1.8 ± 1.5	0.368
Extra-thyroidal extension	36 (62.1)	125 (59.2)	0.697
Multifocality	9 (15.5)	45 (21.3)	0.328
Lymph node metastasis	10 (12.2)	63 (29.9)	0.056
TNM stage
I	35 (60.3)	127 (60.2)	0.983
II–IV	23 (39.7)	84 (39.8)

Percentages are given in parentheses.

^*Fine needle aspiration cytology.

Table IV. AMES stage and MACIS score in patients with papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT) and in patients with PTC alone.

	PTC with HT (n = 58)	PTC alone (n = 211)	p-value
AMES stage
High-risk group	14 (24.1)	62 (29.4)	0.432
Low-risk group	44 (75.9)	149 (70.6)
MACIS score
Mean	5.0 ± 1.3	5.5 ± 1.6	0.030
<6	46 (79.1)	145 (68.7)	0.115
≥6	12 (20.7)	66 (31.3)
6–7	4 (6.9)	32 (15.2)	0.101
7–8	7 (12.1)	18 (8.5)	0.411
≥8	1 (1.7)	16 (7.6)	0.104

Percentages are given in parentheses.

Figure 1. Comparison of disease-free survival (A) and overall survival (B) between the two groups.

Table V. Recurrence and mortality in patients with papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT) and in patients with PTC alone.

	PTC with HT (n = 58)	PTC alone (n = 211)	p-value
Follow-up period (months)	59.0 ± 25.4	62.8 ± 27.0	0.341
Total number of patients with recurrence	4 (6.9)	35 (16.6)	0.063
Total number of patient deaths	0 (0.0)	8 (3.8)	0.132
Disease-specific death	0 (0.0)	2 (1.0)	0.457

Percentages are given in parentheses.